These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33747510)

  • 61. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Approaches to target IgE antibodies in allergic diseases.
    Balbino B; Conde E; Marichal T; Starkl P; Reber LL
    Pharmacol Ther; 2018 Nov; 191():50-64. PubMed ID: 29909239
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Omalizumab: a review of its use in the treatment of allergic asthma.
    Plosker GL; Keam SJ
    BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
    Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
    [No Abstract]   [Full Text] [Related]  

  • 66. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
    Garcia G; Magnan A; Chiron R; Contin-Bordes C; Berger P; Taillé C; Devouassoux G; de Blay F; Couderc LJ; Didier A; O'Callaghan DS; Girodet PO; Bourdeix I; Le Gros V; Humbert M
    Chest; 2013 Aug; 144(2):411-419. PubMed ID: 23579324
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The use of omalizumab in asthma.
    Price D
    Prim Care Respir J; 2008 Jun; 17(2):62-72. PubMed ID: 18425299
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Omalizumab improves asthma-related quality of life in children with allergic asthma.
    Lemanske RF; Nayak A; McAlary M; Everhard F; Fowler-Taylor A; Gupta N
    Pediatrics; 2002 Nov; 110(5):e55. PubMed ID: 12415061
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
    Maggi L; Rossettini B; Montaini G; Matucci A; Vultaggio A; Mazzoni A; Palterer B; Parronchi P; Maggi E; Liotta F; Annunziato F; Cosmi L
    Eur J Immunol; 2018 Dec; 48(12):2005-2014. PubMed ID: 30252930
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
    Hochhaus G; Brookman L; Fox H; Johnson C; Matthews J; Ren S; Deniz Y
    Curr Med Res Opin; 2003; 19(6):491-8. PubMed ID: 14594521
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
    Oliver JM; Tarleton CA; Gilmartin L; Archibeque T; Qualls CR; Diehl L; Wilson BS; Schuyler M
    Int Arch Allergy Immunol; 2010; 151(4):275-84. PubMed ID: 19844128
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.
    D'Amato G; Stanziola A; Sanduzzi A; Liccardi G; Salzillo A; Vitale C; Molino A; Vatrella A; D'Amato M
    Multidiscip Respir Med; 2014; 9(1):23. PubMed ID: 24735949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
    Lowe PJ; Tannenbaum S; Gautier A; Jimenez P
    Br J Clin Pharmacol; 2009 Jul; 68(1):61-76. PubMed ID: 19660004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
    Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
    Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Omalizumab in allergic diseases, a recent review.
    Vichyanond P
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.